Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
Pulmonary Embolism I: Introduction01:19

Pulmonary Embolism I: Introduction

A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic screening of triple negative thrombocytosis patients identifies germline <i>MPL</i> compound mutations and <i>SH2B3/LNK</i> truncating mutations.

Haematologica·2026
Same author

Specific Features of Cerebral Venous Thrombosis Associated With Iron Deficiency Anemia.

Journal of the American Heart Association·2026
Same author

Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial.

European heart journal·2025
Same author

Contraception and risk factors in young women with myocardial infarction: The WAMIF study.

European journal of obstetrics, gynecology, and reproductive biology·2025
Same author

Twice-a-day administration of aspirin in patients with diabetes mellitus or aspirin resistance after acute coronary syndrome: Rationale and design of the randomized ANDAMAN trial.

American heart journal·2025
Same author

Efficacy and Safety of Direct Oral Anti-Coagulants in Painful Venous Malformations in Children.

Pediatric dermatology·2025

Related Experiment Video

Updated: Jun 25, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

Atherothrombosis as a systemic disease.

Ludovic Drouet1

  • 1Laboratoire d'Hématologie, Hôpital Lariboisière, Paris, France. ludovic.drouet@lrb.ap-hop-paris.fr

Cerebrovascular Diseases (Basel, Switzerland)
|January 23, 2002
PubMed
Summary

Atherothrombosis is a widespread arterial disease where plaque rupture forms blood clots, causing ischemic events. Antiplatelet therapy is crucial for preventing these thrombotic complications and protecting all arterial beds.

Area of Science:

  • Cardiovascular Medicine
  • Vascular Biology
  • Thrombosis Research

Background:

  • Atherothrombosis is a systemic arterial disease involving plaque disruption and thrombus formation.
  • Thrombotic events can be clinically silent, contributing to plaque growth or causing microvascular damage.

Purpose of the Study:

  • To highlight the generalized nature of atherothrombosis and its clinical manifestations.
  • To emphasize the importance of managing risk factors and employing antiplatelet therapy for prevention.

Main Methods:

  • Review of the pathophysiology of atherothrombosis.
  • Analysis of the role of platelet-rich thrombi in ischemic events.
  • Discussion of treatment strategies including risk factor management and antiplatelet agents.

More Related Videos

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Related Experiment Videos

Last Updated: Jun 25, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Main Results:

  • Atherothrombosis affects multiple arterial beds, with varying dependency on the vascular territory.
  • Disrupted plaques lead to thrombus formation, causing ischemic events like stroke and myocardial infarction.
  • Subclinical thrombotic events contribute to plaque progression and microvascular damage.

Conclusions:

  • Effective management requires addressing cardiovascular risk factors and implementing antiplatelet therapy.
  • Antiplatelet therapy is essential for preventing acute ischemic events and microembolization.
  • Systemic antiplatelet treatment provides consistent benefits across all arterial beds for atherothrombotic patients.